Study guide

1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role

Key Takeaways Explain This Topic AI

NCRA first offered the CTR credential in 1983; the credential was renamed Oncology Data Specialist (ODS) effective January 1, 2024, and holders may use ODS, ODS-C or ODS-Certified.

Route 1 is an NCRA-accredited associate degree plus practicum; Route 2 is 60 college credits plus an NCRA-accredited certificate and practicum; Route 3 is 60 college credits with two semesters of anatomy and physiology plus 1,950 hours of registry experience.

CoC Standard 4.3 requires case abstracting by an ODS; non-ODS staff may abstract only under a documented ODS supervision plan and must pass the ODS exam within three years of being hired to abstract.

CoC Standard 2.1 lists an Oncology Data Specialist as a required non-physician member of every accredited program's cancer committee.

The NCDB, a joint CoC–American Cancer Society database begun in 1989, receives data from more than 1,500 accredited programs and captures about 72% of newly diagnosed U.S. cancers.

Last updated: September 2026

A new name, the same credential

In 1983 the National Cancer Registrars Association (NCRA), founded in 1974, began certifying cancer registrars as Certified Tumor Registrars (CTRs) . NCRA reports that more than 9,000 people have earned the credential since then and that over 6,000 hold it today. Effective January 1, 2024 , the credential was renamed Oncology Data Specialist (ODS) . The NCI SEER program's guide to becoming a registrar states the date the same way. The change affected the name only. Existing CTRs became ODS-certified without a new exam, and the certification exam, eligibility routes and maintenance rules continued unchanged.

NCRA's Code of Ethics, updated in 2024 for the name change, gives the usage rule directly:

An Oncology Data Specialist should use the letters ODS ; alternatively, ODS-C or ODS-Certified may be used.

ODS (Retired) is used by credential holders the Council on Certification has approved as retired.

CTR (Retired) is used only by those who retired their credential before January 1, 2024.

The new name reflects how much the work has changed. Registrars no longer just record tumors. They interpret pathology, imaging and molecular results, apply national coding rules, and supply data for quality improvement, research and public health.

Eligibility: three routes

Candidates must meet every requirement of one route by the application deadline for the window they choose. The routes were renamed in late 2025 (Routes 1, 2 and 3, formerly A1, A2 and B), but the requirements have not changed since 2010.

Route Education Experience

Route 1 (formerly A1) Completion of an NCRA-accredited associate degree program Completion of the program's practicum, including NCRA's online competency assessments

Route 2 (formerly A2) An associate degree or equivalent (60 college-level credits) plus an NCRA-accredited certificate program Completion of the program's practicum and competency assessments

Route 3 (formerly B) An associate degree or equivalent (60 college-level credits) that includes two college-credited semesters (six credit hours) of human anatomy and human physiology, with a grade of C or better 1,950 hours (one year full time) of cancer registry experience

Other eligibility details worth knowing:

The practicum is built on five competencies : casefinding; abstracting, coding and staging; analysis and data usage; registry organization, follow-up and data quality assurance; and cancer program accreditation.

For Route 3, NCRA expects recent experience covering all basic registry activities, including casefinding, abstracting, follow-up, reporting, cancer committee and cancer conference work, and state or NCDB submissions. A supervisor or human resources representative must verify the hours on the application.

Unofficial transcripts are accepted, and courses recommended for credit by the American Council on Education count toward the 60 credits.

A candidate retaking the exam must meet the eligibility rules in force for that year.

Why accredited programs need ODS professionals

The Commission on Cancer (CoC) builds the credential directly into its 2020 standards, which were updated in October 2025:

CoC standard ODS-related requirement

2.1 Cancer Committee An Oncology Data Specialist is a required non-physician member of the committee. An ODS member may serve only as the Cancer Conference Coordinator and/or the Cancer Registry Quality Coordinator.

4.3 Cancer Registry Staff Credentials Case abstracting is performed by an ODS. Non-credentialed staff may abstract only under a documented ODS supervision plan covering the scope of supervision, quality control, education and training, and they must pass the ODS exam within three years of being hired to abstract. Non-ODS registry staff must complete three hours of cancer-related continuing education each calendar year.

6.1 Cancer Registry Quality Control ODS professionals may serve as quality control reviewers, but they cannot review their own cases.

Standard 4.3 applies whether registry staff are employees, contractors or staff of a registry service company. Non-credentialed staff may do casefinding and follow-up, but they cannot abstract analytic cases outside the supervision plan.

Where ODS professionals work

Setting Main purpose Typical work

Facility (hospital) registry Patient-care evaluation, accreditation, program planning Casefinding, abstracting analytic cases (Class of Case 00–22), staging, annual follow-up, cancer committee and conference support, NCDB submission through the Rapid Cancer Reporting System, and state reporting

Central (population-based) registry Incidence and surveillance for a defined population Consolidating reports from many sources, deduplication and record linkage, death clearance, data release, and submissions to NPCR, SEER and NAACCR

Specialty registry A focused population or research question Registries limited to one cancer site, a clinical trial or research consortium, a pediatric population, or a federal system such as the Veterans Affairs cancer registry

Hospital and central registries are complementary. A hospital registry answers "How well did our program diagnose, treat and follow our patients?" A central registry answers "How much cancer is there in this population , and how is it changing?" The same tumor is often abstracted by several hospitals and consolidated into one record at the central registry.

How the data are used

NCDB. The National Cancer Database is a joint program of the CoC and the American Cancer Society that began in 1989. It receives data from more than 1,500 CoC-accredited programs and captures about 72% of newly diagnosed U.S. cancers. Accredited programs use it to benchmark their quality measures and survival.

Central registries. These supply the population statistics published in U.S. Cancer Statistics . See Chapter 7 for SEER, NPCR and NAACCR.

Program improvement. Registry data feed cancer committee reports, quality improvement initiatives, community outreach planning and clinical trial screening.

Exam traps

CTR and ODS are not two different credentials. The CTR was renamed ODS on January 1, 2024.

CoC does not forbid all non-ODS abstracting. It allows non-ODS abstracting only under a written ODS supervision plan, and only until the three-year deadline to pass the exam.

Hospital registries work with analytic caseloads defined by Class of Case, while central registries aim to include every reportable case in residents of their area, regardless of where care was given.

Loading diagram... How one patient's data flow through the registry system